AstraZeneca To Reclaim Full Rights To Several Drugs From Merck For $647M
By exercising its option, AstraZeneca also positions itself to regain full rights to Nexium and Prilosec as early as 2012.
By exercising its option, AstraZeneca also positions itself to regain full rights to Nexium and Prilosec as early as 2012.